Skip to Content
Merck
All Photos(4)

Key Documents

05-1410-M

Sigma-Aldrich

Anti-CD45 Antibody, clone F10-89-4

clone F10-89-4, from mouse, purified by affinity chromatography

Synonym(s):

CD45 antigen, Leukocyte common antigen precursor, SCID due to PTPRC deficiency, T200 glycoprotein, T200 leukocyte common antigen, Human homolog of severe combined immunodeficiency due to PTPRC deficiency, Leukocyte-common antigen, Protein tyrosine phosph

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

F10-89-4, monoclonal

purified by

affinity chromatography

species reactivity

mouse

species reactivity (predicted by homology)

human, rat

technique(s)

flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG2a

NCBI accession no.

UniProt accession no.

target post-translational modification

unmodified

Gene Information

human ... PTPRC(5788)

General description

CD45 is a receptor-tyrosine phosphatase required for antigen-induced signaling in T-cells and B-cells; its substrates are unknown. Interestingly, it associates with several Src-family tyrosine kinases, which are inhibited by tyrosine phosphorylation in their c-termini, suggesting a mechanism for signaling by CD45.

Specificity

This antibody reacts with the leucocyte common antigen (LCA) complex to be found on lymphocytes, monocytes, granulocytes, thymocytes and malignant T and B cells. No reactivity has been observed with primary or metastatic carcinoma cells. Plasma cells or myeloma cells may have weak expression or be negative for this antigen.
The LCA comprises of at least 5 isoforms ranging from 180-220 kDa which are produced as a result of alternative splicing of exons A, B or C. CBL 124 recognizes epitopes common to
all of the isoforms.
Antigen distribution:
Thymocytes >95%
Granulocytes >95%
Monocytes >95%
B cells (CD20+) >95%
T cells (CD3+) >95%
NK cells (CD16+) >95%
Peripheral blood lymphocytes >95%
FUSION PARTNER: NS1 myeloma cell line

Immunogen

Purified T cells from human lymph nodes

Application

Anti-CD45 Antibody, clone F10-89-4 detects level of CD45 & has been published & validated for use in FC, WB, IF, IP, IH(P).
Immunofluorescence: A previous lot of this antibody was used in the identification of cells of leucocyte origin by indirect staining.

Immunohistochemistry (paraffin): A previous lot of this antibody was used in the discrimination between malignant cells of haematopoietic origin and other malignancies in frozen tissue sections.

Immunoprecipitation: A previous lot of this antibody was used in studies of the leucocyte common antigen complex and its identification by the Western blotting technique.

Flow Cytometry: Studies of CD45 expression and the association with T-cell receptor signaling was performed using this antibody of previous lot.
Studies of the mechanism by which CD45 regulates B cell activation through protein tyrosine phospatases.
Optimal working dilutions must be determined by the end user.

Immunohistochemistry(paraffin): Representative testing from a previous lot.

Optimal Staining of CD45 Monoclonal Antibody: Tonsil
Research Category
Signaling
Research Sub Category
Immunological Signaling

Quality

Routinely evaluated by Western Blot on jurkat cell lysate.

Western Blot Analysis: 1:500 dilution of this lot detected CD45 on 10 μg of Jurkat lysates

Target description

~180-220 kDa

Linkage

Replaces: 04-1102

Physical form

Protein A affinity chromatography
Purified mouse monoclonal IgG2a presented in phosphate buffered saline containing 10 mM sodium azide and 1 mg/mL bovine serum albumin.
We recommend that each laboratory determine an optimum working titre for use in its particular application.

Storage and Stability

For use within 1 month of purchase store at 2-8°C, for long term storage aliquot antibody into small volumes and store at -20°C for up to one year from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Analysis Note

Control
Jurkat cell lysate

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Increased Infiltration of Extra-Cardiac Cells in Myxomatous Valve Disease.
Sauls, K; Toomer, K; Williams, K; Johnson, AJ; Markwald, RR; Hajdu, Z; Norris, RA
Journal of cardiovascular development and disease null
The effect of stromal cell-derived factor-1?/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration.
Jian Yu,Aijun Wang,Zhenyu Tang,Jeffrey Henry,Benjamin Li-Ping Lee,Yiqian Zhu,Failei Yuan et al.
Biomaterials null
Olena Preobrazhenska et al.
PloS one, 7(6), e39761-e39761 (2012-07-05)
Chronic obstructive lung disease (COPD) is characterized by matrix deposition in the small airways but matrix loss from the parenchyma, phenomena which must depend on the ability of local fibroblasts to produce matrix after smoke exposure. To investigate this idea

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service